Literature DB >> 7387145

Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.

J R Hess, S J Berman, W H Boughton, J G Sugihara, J E Musgrave, E G Wong, A M Siemsen.   

Abstract

The pharmacokinetics of ceforanide were evaluated in 11 patients with end stage renal disease (creatinine clearance less than 5 ml/min). A single intravenous dose of 750 mg/m2 produced peak plasma concentrations of 123 +/- 29 microgram/ml. The plasma half-life (T 1/2) of the drug was 19.1 +/- 2.5 h. A 5.5 h hemodialysis session removed 53% of the drug and reduced the T 1/2 to 5 +/- 0.7 h. Plasma concentrations greater than 10 microgram/m2 were maintained without adverse effects with a 1.5-g/m2 dose administered three times a week for 2 weeks.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7387145      PMCID: PMC283766          DOI: 10.1128/AAC.17.2.251

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Pharmacokinetics and clinical use of cephalosporin antibiotics.

Authors:  C H Nightingale; D S Greene; R Quintiliani
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  Hemodialysis-associated infections: treatment with cephapirin.

Authors:  S J Berman; W H Boughton; J G Sugihara; E G Wong; A W Siemsen
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

3.  Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency.

Authors:  W A Craig; P G Welling; T C Jackson; C M Kunin
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

4.  Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis.

Authors:  S J Berman; W H Boughton; J G Sugihara; E G Wong; M M Sato; A W Siemsen
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

5.  Laboratory evaluation of BL-S786, a cephalosporin with broad-spectrum antibacterial activity.

Authors:  F Leitner; M Misiek; T A Pursiano; R E Buck; D R Chisholm; R G DeRegis; Y H Tsai; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

6.  In vitro and in vivo studies with BL-S786, cefoxitin, and cefamandole.

Authors:  S Shadomy; G Wagner; M Carver
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

7.  In vitro activity and beta-lactamase stability of BL-S786 compared with those of other cephalosporins.

Authors:  N Aswapokee; P Aswapokee; K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

8.  Ceforanide: in vitro and clinical evaluation.

Authors:  K H Burch; D Pohlod; L D Saravolatz; T Madhavan; D Kiani; E L Quinn; R Del Busto; J Cardenas; E J Fisher
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

  8 in total
  3 in total

Review 1.  Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D M Campoli-Richards; T E Lackner; J P Monk
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 3.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.